On Invalid Date, Hutchmed (NASDAQ: HCM) reported Q2 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Hutchmed earnings for the quarter were N/A. In the same quarter last year, Hutchmed's earnings per share (EPS) was N/A.
As of Q4 2023, Hutchmed's earnings has grown year over year. Hutchmed's earnings in the past year totalled -$29.42 million.
What was HCM's revenue last quarter?
On Invalid Date, Hutchmed (NASDAQ: HCM) reported Q2 2023 revenue of N/A up N/A year over year. In the same quarter last year, Hutchmed's revenue was N/A.
What was HCM's revenue growth in the past year?
As of Q4 2023, Hutchmed's revenue has grown 88.93% year over year. This is 77.74 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 11.19%. Hutchmed's revenue in the past year totalled $757.24 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.